JOURNEY MEDICAL CORPOR

NetDania - New 12 months High: JOURNEY MEDICAL CORPORATION - COMMON STOCK

20 ديسمبر 2023 13:19:59 بحسب NetDania Notify

NetDania - New 12 months High: JOURNEY MEDICAL CORPORATION - COMMON STOCK

19 ديسمبر 2023 09:45:11 بحسب NetDania Notify

NetDania - New 12 months High: JOURNEY MEDICAL CORPORATION - COMMON STOCK

18 ديسمبر 2023 10:50:29 بحسب NetDania Notify

NetDania - New 12 months High: JOURNEY MEDICAL CORPORATION - COMMON STOCK

07 ديسمبر 2023 09:45:04 بحسب NetDania Notify

NetDania - New 12 months High: JOURNEY MEDICAL CORPORATION - COMMON STOCK

06 ديسمبر 2023 10:26:29 بحسب NetDania Notify

Journey Medical Corporation Announces Successful Completion of Pre-NDA Meeting with the FDA for DFD-29 to Treat Rosacea

06 ديسمبر 2023 08:00:51 بحسب Nasdaq GlobeNewswire

Journey Medical Corporation Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights

07 نوفمبر 2023 16:01:18 بحسب Nasdaq GlobeNewswire

Journey Medical Corporation to Announce Third Quarter 2023 Financial Results on November 7, 2023

31 أكتوبر 2023 08:30:12 بحسب Nasdaq GlobeNewswire

Journey Medical Corporation Announces Data from Bioavailability Study of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) vs. Solodyn® (Minocycline Hydrochloride Extended-Release Tablets, 105 mg)

20 أكتوبر 2023 08:30:59 بحسب Nasdaq GlobeNewswire

Journey Medical Corporation Enters into an Exclusive License Agreement with Maruho Co., Ltd. for Qbrexza® in South Korea and Other Asian Nations

06 سبتمبر 2023 08:00:04 بحسب Nasdaq GlobeNewswire

Journey Medical Corporation Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights

08 أغسطس 2023 16:01:33 بحسب Nasdaq GlobeNewswire

Journey Medical Corporation to Announce Second Quarter 2023 Financial Results on August 8, 2023

02 أغسطس 2023 16:01:42 بحسب Nasdaq GlobeNewswire

Journey Medical Corporation to Announce Second Quarter 2023 Financial Results the Week of August 7, 2023

19 يوليو 2023 08:30:00 بحسب Nasdaq GlobeNewswire

Journey Medical Corporation Announces Positive Topline Results from its Two Phase 3 Clinical Trials (MVOR-1 and MVOR-2) Evaluating DFD-29 for the Treatment of Papulopustular Rosacea in Adults

11 يوليو 2023 08:30:20 بحسب Nasdaq GlobeNewswire

Journey Medical Corporation Expects Topline Results from the Phase 3 Clinical Trials (MVOR-1 and MVOR-2) Evaluating DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) for the Treatment of Papulopustular Rosacea to be Announced Week of July 10, 2023

03 يوليو 2023 08:00:00 بحسب Nasdaq GlobeNewswire

Journey Medical Corporation Announces Positive Topline Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on Microbial Flora of Healthy Adult Subjects

13 يونيو 2023 08:30:59 بحسب Nasdaq GlobeNewswire

Journey Medical Corporation Reports First Quarter 2023 Financial Results and Recent Corporate Highlights

22 مايو 2023 16:01:31 بحسب Nasdaq GlobeNewswire

Journey Medical Corporation to Announce First Quarter 2023 Financial Results on May 22, 2023

19 مايو 2023 16:01:27 بحسب Nasdaq GlobeNewswire

Journey Medical Corporation Announces Postponement of First Quarter Financial Results Release and Conference Call

11 مايو 2023 16:01:01 بحسب Nasdaq GlobeNewswire

Journey Medical Corporation to Announce First Quarter 2023 Financial Results on May 11, 2023

04 مايو 2023 09:00:26 بحسب Nasdaq GlobeNewswire